Claire Harrison, MD, shares results from the phase 3 MANIFEST-2 evaluating the clinical efficacy of pelabresib combined with ruxolitinib compared with ruxolitinib alone for patients with myelofibrosis naïve to JAK inhibitor therapy.
Claire Harrison, MD, shares results from the phase 3 MANIFEST-2 evaluating the clinical efficacy of pelabresib combined with ruxolitinib compared with ruxolitinib alone for patients with myelofibrosis naïve to JAK inhibitor therapy.
True or False: The small-molecular BET inhibitor INCB057643 demonstrated promising clinical activity and tolerability both as a monotherapy and combined with ruxolitinib for patients with relapsed/refractory myelofibrosis.
True or False: The small-molecular BET inhibitor INCB057643 demonstrated promising clinical activity and tolerability both as a monotherapy and combined with ruxolitinib for patients with relapsed/refractory myelofibrosis.
True or False: According to results from the EPCORE NHL-2 clinical trial, the addition of epcoritamab to standard R-ICE therapy demonstrated high overall and complete response rates among patients with R/R DLBCL eligible for autologous stem...
True or False: According to results from the EPCORE NHL-2 clinical trial, the addition of epcoritamab to standard R-ICE therapy demonstrated high overall and complete response rates among patients with R/R DLBCL eligible for autologous stem...
The implementation of R-ICE combined with genotype-guided therapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma demonstrated clinical efficacy and safety in a phase 2 trial.
The implementation of R-ICE combined with genotype-guided therapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma demonstrated clinical efficacy and safety in a phase 2 trial.
Treatment of R/R diffuse large B-cell lymphoma with PD-1/PD-L1 inhibitors alone showed consistent safety but limited efficacy, while combination treatment with CAR T-cell therapy demonstrated potential improved outcomes.
Treatment of R/R diffuse large B-cell lymphoma with PD-1/PD-L1 inhibitors alone showed consistent safety but limited efficacy, while combination treatment with CAR T-cell therapy demonstrated potential improved outcomes.
Compared with traditional salvage therapies, polatuzumab vedotin and zanubrutinib combined with rituximab or obinutuzumab demonstrated encouraging clinical efficacy for patients with relapsed/refractory diffuse large B-cell lymphoma.
Compared with traditional salvage therapies, polatuzumab vedotin and zanubrutinib combined with rituximab or obinutuzumab demonstrated encouraging clinical efficacy for patients with relapsed/refractory diffuse large B-cell lymphoma.
In a phase 2 study, MRG002 demonstrated manageable safety profile and promising anti-tumor activity among patients with locally advanced or metastatic breast cancer with low HER2 expression.
In a phase 2 study, MRG002 demonstrated manageable safety profile and promising anti-tumor activity among patients with locally advanced or metastatic breast cancer with low HER2 expression.
Pexidartinib showed sustained clinical benefit among patients with tenosynovial giant cell tumor associated with severe morbidity or functional limitations and not amenable to surgery.
Pexidartinib showed sustained clinical benefit among patients with tenosynovial giant cell tumor associated with severe morbidity or functional limitations and not amenable to surgery.
From administration innovations to trial-backed insights, this video series explores how OBI may improve treatment flow, reduce chair time, and fit within today’s multiple myeloma care models. Stream video 1 today!
Claire Harrison, MD, shares results from the phase 3 MANIFEST-2 evaluating the clinical efficacy of pelabresib combined with ruxolitinib compared with ruxolitinib alone for patients with myelofibrosis naïve to JAK inhibitor therapy.
Claire Harrison, MD, shares results from the phase 3 MANIFEST-2 evaluating the clinical efficacy of pelabresib combined with ruxolitinib compared with ruxolitinib alone for patients with myelofibrosis naïve to JAK inhibitor therapy.
Nicolas Girard, MD, discusses results from the PALOMA-2 trial which assessed the efficacy and safety of first-line subcutaneous amivantamab, administered once every 4 weeks, plus lazertinib among patients with EGFR-mutated non-small cell lung...
Nicolas Girard, MD, discusses results from the PALOMA-2 trial which assessed the efficacy and safety of first-line subcutaneous amivantamab, administered once every 4 weeks, plus lazertinib among patients with EGFR-mutated non-small cell lung...
Drew Moghanaki, MD, MPH, University of California, Los Angeles, discusses whether patients with resectable lung cancer should be offered a chemo-radiation approach.
Drew Moghanaki, MD, MPH, University of California, Los Angeles, discusses whether patients with resectable lung cancer should be offered a chemo-radiation approach.
Olatunji Alese, MD, discusses the use of dual immune checkpoint blockade, for frontline therapy and sequencing, for patients with advanced hepatocellular carcinoma.
Olatunji Alese, MD, discusses the use of dual immune checkpoint blockade, for frontline therapy and sequencing, for patients with advanced hepatocellular carcinoma.
Join our virtual educational programs from September 29 through December 1 to advance your understanding of the diversity of patient types in R/R follicular lymphoma. Do not miss out on this free educational program. Pick the time that works best for your schedule!
Raajit Rampal, MD, PhD shares results from a real-world analysis evaluating outcomes and hemoglobin responses among patients with myelofibrosis who were treated with pacritinib.
Raajit Rampal, MD, PhD shares results from a real-world analysis evaluating outcomes and hemoglobin responses among patients with myelofibrosis who were treated with pacritinib.
John Strickler, MD, discusses results from the CodeBreaK 101 study which assessed the addition of FOLFIRI to sotorasib and panitumumab among patients with KRAS G12C-mutated metastatic colorectal cancer.
John Strickler, MD, discusses results from the CodeBreaK 101 study which assessed the addition of FOLFIRI to sotorasib and panitumumab among patients with KRAS G12C-mutated metastatic colorectal cancer.
Amer Zeidan, MBBS, MHS, shares results from a phase 2 trial determining the safety and efficacy of decitabine-cedazuridine plus venetoclax for patients with newly diagnosed acute myeloid leukemia ineligible for induction chemotherapy.
Amer Zeidan, MBBS, MHS, shares results from a phase 2 trial determining the safety and efficacy of decitabine-cedazuridine plus venetoclax for patients with newly diagnosed acute myeloid leukemia ineligible for induction chemotherapy.
Meghan Mooradian, MD, discusses primary analysis results from the phase 2 NEO-MEL-T trial, which showed that neoadjuvant dostarlimab plus cobolimab demonstrated promising efficacy and safety among patients with high-risk resectable melanoma.
Meghan Mooradian, MD, discusses primary analysis results from the phase 2 NEO-MEL-T trial, which showed that neoadjuvant dostarlimab plus cobolimab demonstrated promising efficacy and safety among patients with high-risk resectable melanoma.
Nick James, MD, PhD, discusses results from a study which assessed using a multimodal artificial intelligence algorithm to identify patients with high-risk non-metastatic prostate cancer who are most likely to benefit from adding a...
Nick James, MD, PhD, discusses results from a study which assessed using a multimodal artificial intelligence algorithm to identify patients with high-risk non-metastatic prostate cancer who are most likely to benefit from adding a...
Stephen Bagley, MD, discusses results from a phase 1 dose-exploration study which assessed intracerebroventricular delivery of CART-EGFR-IL13Rα2 among patients with recurrent glioblastoma.
Stephen Bagley, MD, discusses results from a phase 1 dose-exploration study which assessed intracerebroventricular delivery of CART-EGFR-IL13Rα2 among patients with recurrent glioblastoma.
Zeynep Eroglu, MD, discusses results from the SWOG S2000 study which demonstrated that encorafenib plus binimetinib and nivolumab significantly improved progression-free survival compared to ipilimumab plus nivolumab among patients with...
Zeynep Eroglu, MD, discusses results from the SWOG S2000 study which demonstrated that encorafenib plus binimetinib and nivolumab significantly improved progression-free survival compared to ipilimumab plus nivolumab among patients with...
Herbert Loong, MD, discusses results from the SOHO-01 trial which showed that BAY 2927088 demonstrated promising efficacy and safety among patients with HER2-mutated non-small cell lung cancer.
Herbert Loong, MD, discusses results from the SOHO-01 trial which showed that BAY 2927088 demonstrated promising efficacy and safety among patients with HER2-mutated non-small cell lung cancer.
Georgina Long, MD, PhD, discusses primary results from the RELATIVITY-098 trial, which demonstrated that adjuvant nivolumab plus relatimab did not significantly improve outcomes compared to adjuvant nivolumab monotherapy among patients with...
Georgina Long, MD, PhD, discusses primary results from the RELATIVITY-098 trial, which demonstrated that adjuvant nivolumab plus relatimab did not significantly improve outcomes compared to adjuvant nivolumab monotherapy among patients with...
Alexander Van Akkooi, MD, PhD, discusses primary analysis results from the EORTC 2139-MG/Columbus-AD trial which demonstrated that adjuvant encorafenib plus binimetinib demonstrates clinical promise among patients with BRAF-mutated melanoma.
Alexander Van Akkooi, MD, PhD, discusses primary analysis results from the EORTC 2139-MG/Columbus-AD trial which demonstrated that adjuvant encorafenib plus binimetinib demonstrates clinical promise among patients with BRAF-mutated melanoma.
Jonathan Riess, MD, discusses phase 2 study results which demonstrated that IO102-IO103 plus pembrolizumab shows clinical promise as a first-line treatment option for patients with advanced squamous cell carcinoma of the head and neck.
Jonathan Riess, MD, discusses phase 2 study results which demonstrated that IO102-IO103 plus pembrolizumab shows clinical promise as a first-line treatment option for patients with advanced squamous cell carcinoma of the head and neck.
Elisabeth Livingstone, MD, discusses results from the phase 2 ImmunoCobiVem trial which evaluated an early switch from targeted therapy to immunotherapy for patients with advanced BRAF V600-positive melanoma.
Elisabeth Livingstone, MD, discusses results from the phase 2 ImmunoCobiVem trial which evaluated an early switch from targeted therapy to immunotherapy for patients with advanced BRAF V600-positive melanoma.
Andrea Botticelli, MD, PhD, discusses final results from the phase 2 ROME trial which demonstrated that using comprehensive genome profiling to guide treatment can improve response and survival among pretreated patients with metastatic solid...
Andrea Botticelli, MD, PhD, discusses final results from the phase 2 ROME trial which demonstrated that using comprehensive genome profiling to guide treatment can improve response and survival among pretreated patients with metastatic solid...
Sung Gwe Ahn, MD, PhD, discusses exploratory analysis results from the HERA trial which demonstrated that the addition of ovarian function suppression to antihormonal therapy shows promise in patients with HR-positive, HER2-positive early...
Sung Gwe Ahn, MD, PhD, discusses exploratory analysis results from the HERA trial which demonstrated that the addition of ovarian function suppression to antihormonal therapy shows promise in patients with HR-positive, HER2-positive early...
Giuseppe Viale, MD, discusses results from a comparison study which demonstrated that reassessing local and central immunostaining results can identify more patients with HER2-low or HER2-ultralow expression eligible for trastuzumab...
Giuseppe Viale, MD, discusses results from a comparison study which demonstrated that reassessing local and central immunostaining results can identify more patients with HER2-low or HER2-ultralow expression eligible for trastuzumab...
According to results from the updated analysis of the ShortHER trial, tumor-infiltrating lymphocyte score is predictive of overall survival and may potentially be used to guide trastuzumab de-escalation among patients with HER2-negative early...
According to results from the updated analysis of the ShortHER trial, tumor-infiltrating lymphocyte score is predictive of overall survival and may potentially be used to guide trastuzumab de-escalation among patients with HER2-negative early...
Andrea Necchi, MD, discusses results from the SunRISe-4 study which assessed the addition of TAR-200 to neoadjuvant cetrelimab in a cohort of patients with muscle-invasive bladder cancer who either refused or were ineligible for...
Andrea Necchi, MD, discusses results from the SunRISe-4 study which assessed the addition of TAR-200 to neoadjuvant cetrelimab in a cohort of patients with muscle-invasive bladder cancer who either refused or were ineligible for...
According to results from the phase 2 Neo-CheckRay trial, the addition of durvalumab and oleclumab to standard SBRT and neoadjuvant chemotherapy demonstrates promise among patients with ER-positive, HER2-negative, high-risk early breast...
According to results from the phase 2 Neo-CheckRay trial, the addition of durvalumab and oleclumab to standard SBRT and neoadjuvant chemotherapy demonstrates promise among patients with ER-positive, HER2-negative, high-risk early breast...
Alberto Montero, MD, discusses phase 1/2 study results which demonstrated that STX-478 shows promise in patients with heavily pre-treated PI3Kα-mutated solid tumors.
Alberto Montero, MD, discusses phase 1/2 study results which demonstrated that STX-478 shows promise in patients with heavily pre-treated PI3Kα-mutated solid tumors.
Georgina Long, MD, PhD, discusses 3-year follow-up results from the phase 3 CheckMate 76K trial which demonstrated that adjuvant nivolumab continued to sustain clinical benefit among patients with resected stage IIB/IIC melanoma.
Georgina Long, MD, PhD, discusses 3-year follow-up results from the phase 3 CheckMate 76K trial which demonstrated that adjuvant nivolumab continued to sustain clinical benefit among patients with resected stage IIB/IIC melanoma.
Join Dr Ellen Ritchie for a 3-video series on a guideline-preferred treatment option for low- and high-risk adult patients with PV, including safety, efficacy, and long-term data. Stream the video series today!
Tune in to Dr Rami Komrokji and Dr Thomas LeBlanc’s discussion on unmet needs in the AML treatment landscape and clinicians’ perspectives. Learn more by streaming the video today!
Treatment sequencing for metastatic BRAF wild-type melanoma is anything but straightforward. Experts bring bold perspectives, challenge each other’s views, and spark thought-provoking discussion. Catch the highlights and dive into more soundbites from the debate.
The implementation of R-ICE combined with genotype-guided therapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma demonstrated clinical efficacy and safety in a phase 2 trial.
The implementation of R-ICE combined with genotype-guided therapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma demonstrated clinical efficacy and safety in a phase 2 trial.
Treatment of R/R diffuse large B-cell lymphoma with PD-1/PD-L1 inhibitors alone showed consistent safety but limited efficacy, while combination treatment with CAR T-cell therapy demonstrated potential improved outcomes.
Treatment of R/R diffuse large B-cell lymphoma with PD-1/PD-L1 inhibitors alone showed consistent safety but limited efficacy, while combination treatment with CAR T-cell therapy demonstrated potential improved outcomes.
Compared with traditional salvage therapies, polatuzumab vedotin and zanubrutinib combined with rituximab or obinutuzumab demonstrated encouraging clinical efficacy for patients with relapsed/refractory diffuse large B-cell lymphoma.
Compared with traditional salvage therapies, polatuzumab vedotin and zanubrutinib combined with rituximab or obinutuzumab demonstrated encouraging clinical efficacy for patients with relapsed/refractory diffuse large B-cell lymphoma.
Pexidartinib showed sustained clinical benefit among patients with tenosynovial giant cell tumor associated with severe morbidity or functional limitations and not amenable to surgery.
Pexidartinib showed sustained clinical benefit among patients with tenosynovial giant cell tumor associated with severe morbidity or functional limitations and not amenable to surgery.
For patients with relapsed/refractory multiple myeloma, the combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated promising clinical efficacy and a manageable safety profile.
For patients with relapsed/refractory multiple myeloma, the combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated promising clinical efficacy and a manageable safety profile.
Results from the phase 2/3 GENERATE study demonstrated that neither mFOLFIRINOX nor S-IROX improved survival results compared to nab-paclitaxel plus gemcitabine among patients with recurrent or metastatic pancreatic cancer in the first-line...
Results from the phase 2/3 GENERATE study demonstrated that neither mFOLFIRINOX nor S-IROX improved survival results compared to nab-paclitaxel plus gemcitabine among patients with recurrent or metastatic pancreatic cancer in the first-line...
According to a phase 2a trial, the novel anti-CSF1 receptor monoclonal antibody, AMB-05X, was found to have favorable pharmacokinetics, pharmacodynamics, efficacy, and safety among patients with tenosynovial giant cell tumors.
According to a phase 2a trial, the novel anti-CSF1 receptor monoclonal antibody, AMB-05X, was found to have favorable pharmacokinetics, pharmacodynamics, efficacy, and safety among patients with tenosynovial giant cell tumors.
According to an analysis of the FDA Adverse Events Reporting System (FAERS) database, the overall safety profile of pexidartinib was generally consistent with the clinical trial findings.
According to an analysis of the FDA Adverse Events Reporting System (FAERS) database, the overall safety profile of pexidartinib was generally consistent with the clinical trial findings.
According to results from the phase 2 E-BiTS study, intrapatient escalation of biweekly trifluridine/tipiracil plus bevacizumab demonstrated promising efficacy and safety among patients with advanced or unresectable metastatic colorectal...
According to results from the phase 2 E-BiTS study, intrapatient escalation of biweekly trifluridine/tipiracil plus bevacizumab demonstrated promising efficacy and safety among patients with advanced or unresectable metastatic colorectal...
